Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06755866

DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer

To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Esophageal Cancer Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yunnan Cancer Hospital

Kunming, Yunnan, China

Location status: Recruiting

Location contact

Guojun Zhang

CONTACT

r 0871-68173640

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 18 years of age and older;
  • First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy;
  • The clinical stage is cT1b~cT2N+; or the clinical stage is cT3~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer);
  • There are no contraindications to MRI examination

Exclusion criteria

  • Have other primary tumors;
  • The image quality does not meet the diagnostic criteria;
  • Those who do not cooperate with the inspection;
  • Patients who have received prior chemoradiotherapy

Treatment and study plan

The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer

Diagnostic Test

Chest MRI scan outside of standard treatment options

Primary outcomes

  1. Tumor response assessment

    Time frame: Surgery was performed within one month after neoadjuvant therapy, and the pathological pCR of the pathological results obtained from the surgery was used as the gold standard in this study to evaluate tumor treatment response

    This study aims to assess tumor treatment response using pathology gold standard pCR . pCR refers to the state in which the pathological tumor completely disappears after systemic therapy, such as chemotherapy, targeted therapy, or endocrine therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

ruiling Yang

CONTACT

[email protected]

17390212095

zhenhui Li

CONTACT

[email protected]

13698736132

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 1, 2025
Registry last updated
Jan 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.